Marka Turco News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marka turco. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marka Turco Today - Breaking & Trending Today

First of its kind 'J-Valve' surgery performed at Christ Hospital

The successful procedure was done by Dr. Dean Kereiakes, Dr. Santiago Garcia and the team at The Lindner Research Center at The Christ Hospital Health Network earlier this month. ....

United States , Marka Turco , National Co , Lindner Research Center , Christ Hospital Heart Vascular Institute , Vascular Institute , Christ Hospital Health Network , Lindner Research Center The , Dean Kereiakes , Santiago Garcia , Christ Hospital Heart , Genesis Medtech , Christ Hospital Health , Early Feasibility , National Co Principal Investigator , North American , Vascular Intervention North America ,

GENESIS MEDTECH NAMES INAUGURAL PRESIDENT TO DRIVE COMMERCIAL STRATEGY FOR NORTH AMERICA

/PRNewswire/ Genesis MedTech Group (Genesis or Group) is pleased to announce its appointment of Dr. Mark A. Turco (Dr. Turco), M.D., F.A.C.C., as President. ....

United States , Washington Adventist Hospital , Warren Wang , Marka Turco , Vascular Research At Washington Adventist Hospital , Prnewswire Genesis Medtech Group Or , Genesis Medtech Group , Jc Medical Inc , Medtronic Inc , Imedtech Group , Genesis Medtech Intervention , North America , Vascular Interventions , Structural Heart Franchises , North American , Genesis Medtech , Cardiac Implants , Interventional Cardiologist , Vascular Research , Vice President , Chief Medical Officer , Structural Heart ,

DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient

Press release content from PR Newswire. The AP news staff was not involved in its creation.
DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient
May 10, 2021 GMT
Sirtex DOORwaY-90 Study Logo
First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres® Y-90 resin microspheres taking place in 15 sites across the U.S.
WOBURN, Mass., May 10, 2021 /PRNewswire/ Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the first patient has been enrolled in DOORwaY-90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma (HCC). ....

United States , Comunidad Autonoma De Cataluna , Cheenu Kappadath , Armeen Mahvash , Marka Turco , Douglas Murrey , Imaging Associates , Providence Sacred Heart Medical Center , Development For Sirtex , European Union Ce Mark , Sirtex Pty Ltd , Interventional Radiologist At Inland Imaging Associates , Objective Response , Inland Imaging Associates , Global Chief Medical Officer , Barcelona Clinic Liver Cancer , Interventional Radiologist , Spheres Pty , European Union , Premarket Approval , ஒன்றுபட்டது மாநிலங்களில் , காமுனிடட தன்னாட்சி டி கடலுள் , மார்க்கா டர்கோ , இமேஜிங் கூட்டாளிகள் , ப்ராவிடெந்ஸ் புனிதமானது இதயம் மருத்துவ மையம் , ஐரோப்பிய தொழிற்சங்கம் ஸ் குறி ,